Platelet activating factor (PAF) antagonists: development of a highly potent PAF antagonist, TCV-309.
Takatani
M
M
Chemistry Res. Labs, Takeda Chemical Industries, LTD., Osaka, Japan.
Maezaki
N
N
Imura
Y
Y
Terashita
Z
Z
Nishikawa
K
K
Tsushima
S
S
D000818:Animals; D001381:Azepines / Q000494:pharmacology; D006801:Humans; D007546:Isoquinolines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D015394:Molecular Structure; D009536:Niacinamide / Q000031:analogs & derivatives / Q000138:chemical synthesis; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D011726:Pyridinium Compounds / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D013329:Structure-Activity Relationship; D044005:Tetrahydroisoquinolines; D014230:Triazoles / Q000494:pharmacology
D001381:Azepines; D007546:Isoquinolines; D010972:Platelet Activating Factor; D011726:Pyridinium Compounds; D044005:Tetrahydroisoquinolines; D014230:Triazoles; C053321:CV 6209; C052518:WEB 2086; D009536:Niacinamide; C067430:TCV 309